Inspire(US:INSP) Globenewswire·2025-12-29 21:11Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which concealed significant operational failures that ultimately led to a drastic cut in guidance and a stock price crash [3][5]. - Key undisclosed operational issues include: - Medicare claims software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device impacted demand for the new Inspire V, leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026, to discuss their legal rights [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [5].